Brian DiCarlo

613 total citations
11 papers, 162 citations indexed

About

Brian DiCarlo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Brian DiCarlo has authored 11 papers receiving a total of 162 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Brian DiCarlo's work include HER2/EGFR in Cancer Research (4 papers), Advanced Breast Cancer Therapies (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Brian DiCarlo is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Advanced Breast Cancer Therapies (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Brian DiCarlo collaborates with scholars based in United States and China. Brian DiCarlo's co-authors include Ravi Patel, Robert M. Elashoff, J. Randolph Hecht, Haijun Wang, David W. Chan, William Lawler, Sara A. Hurvitz, Dennis J. Slamon, Nicholas P. McAndrew and Kathleen Kennedy and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Brian DiCarlo

10 papers receiving 161 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian DiCarlo United States 7 105 92 45 24 23 11 162
Светлана Проценко Russia 5 138 1.3× 102 1.1× 50 1.1× 26 1.1× 9 0.4× 11 184
Enrico Caliman Italy 9 145 1.4× 81 0.9× 60 1.3× 22 0.9× 32 1.4× 24 219
Wendong Lei China 4 84 0.8× 47 0.5× 39 0.9× 16 0.7× 16 0.7× 10 126
Tea Zeppola Italy 5 95 0.9× 52 0.6× 36 0.8× 18 0.8× 50 2.2× 6 134
Juergen Krauss Germany 7 116 1.1× 47 0.5× 53 1.2× 21 0.9× 12 0.5× 14 167
Lauren Carcas United States 4 69 0.7× 54 0.6× 92 2.0× 42 1.8× 54 2.3× 5 186
David Vicente Baz Spain 10 173 1.6× 138 1.5× 52 1.2× 17 0.7× 29 1.3× 27 235
Effie Skrinos Australia 4 109 1.0× 55 0.6× 43 1.0× 44 1.8× 21 0.9× 8 151
Mojca Unk Slovenia 6 134 1.3× 117 1.3× 24 0.5× 15 0.6× 23 1.0× 14 193
M. Naomi Horiba United States 7 93 0.9× 45 0.5× 78 1.7× 49 2.0× 28 1.2× 12 186

Countries citing papers authored by Brian DiCarlo

Since Specialization
Citations

This map shows the geographic impact of Brian DiCarlo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian DiCarlo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian DiCarlo more than expected).

Fields of papers citing papers by Brian DiCarlo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian DiCarlo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian DiCarlo. The network helps show where Brian DiCarlo may publish in the future.

Co-authorship network of co-authors of Brian DiCarlo

This figure shows the co-authorship network connecting the top 25 collaborators of Brian DiCarlo. A scholar is included among the top collaborators of Brian DiCarlo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian DiCarlo. Brian DiCarlo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
2.
Zhang, Jian, Nicholas P. McAndrew, Xiaojia Wang, et al.. (2023). Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor. Breast Cancer Research. 25(1). 81–81. 9 indexed citations
3.
Hurvitz, Sara A., David W. Chan, Thomas J. Lomis, et al.. (2022). TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.. Journal of Clinical Oncology. 40(16_suppl). TPS623–TPS623. 21 indexed citations
4.
Noor, Zorawar S., Jonathan W. Goldman, William Lawler, et al.. (2019). Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer. Lung Cancer. 135. 104–109. 10 indexed citations
5.
Hurvitz, Sara A., Julie Taguchi, David W. Chan, et al.. (2018). Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09). Therapeutic Advances in Medical Oncology. 10. 3861422379–3861422379. 25 indexed citations
6.
Wainberg, Zev A., Heloisa P. Soares, Ravi Patel, et al.. (2015). Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers. Cancer Chemotherapy and Pharmacology. 76(1). 61–67. 16 indexed citations
7.
Hamilton, Erika, Michael J. Birrer, Brian DiCarlo, et al.. (2015). A phase 1b, open-label, non-randomized multicenter study of birinapant in combination with conatumumab in subjects with relapsed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.. Journal of Clinical Oncology. 33(15_suppl). 5571–5571. 6 indexed citations
8.
Kabbinavar, Fairooz F., Nazy Zomorodian, Matthew B. Rettig, et al.. (2014). An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC).. Journal of Clinical Oncology. 32(4_suppl). 169–169. 5 indexed citations
9.
Kabbinavar, Fairooz F., Nazy Zomorodian, Matthew B. Rettig, et al.. (2014). An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC).. Journal of Clinical Oncology. 32(15_suppl). 5073–5073. 3 indexed citations
10.
11.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Светлана Проценко Breakdown of academic impact, for papers by Enrico Caliman Breakdown of academic impact, for papers by Wendong Lei Breakdown of academic impact, for papers by Tea Zeppola Breakdown of academic impact, for papers by Juergen Krauss Breakdown of academic impact, for papers by Lauren Carcas Breakdown of academic impact, for papers by David Vicente Baz Breakdown of academic impact, for papers by Effie Skrinos Breakdown of academic impact, for papers by Mojca Unk Breakdown of academic impact, for papers by M. Naomi Horiba
Rankless by CCL
2026